<!DOCTYPE html>
<html lang="en-us"
  dir="ltr">

<head>
  <meta charset="utf-8">
<meta name="viewport" content="width=device-width">



<link rel="icon" type="image/ico" href="https://reports.muthu.co/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://reports.muthu.co/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://reports.muthu.co/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="192x192" href="https://reports.muthu.co/android-chrome-192x192.png">
<link rel="apple-touch-icon" sizes="180x180" href="https://reports.muthu.co/apple-touch-icon.png">

<meta name="description" content=""/>



<title>
    
    J B Chemicals &amp; Pharmaceuticals Ltd:Annual Report 2023-24 Analysis | Financial Report Insights
    
</title>
<link href="/_pagefind/pagefind-ui.css" rel="stylesheet">
<script src="/_pagefind/pagefind-ui.js"></script>
<link rel="canonical" href="https://reports.muthu.co/posts/j-b-chemicals--pharmaceuticals-ltdannual-report-2023-24-analysis/"/>

<meta property="og:url" content="https://reports.muthu.co/posts/j-b-chemicals--pharmaceuticals-ltdannual-report-2023-24-analysis/">
  <meta property="og:site_name" content="Financial Report Insights">
  <meta property="og:title" content="J B Chemicals & Pharmaceuticals Ltd:Annual Report 2023-24 Analysis">
  <meta property="og:description" content="JB Chemicals &amp; Pharmaceuticals Ltd.: A Comprehensive Overview # About the Company # Year of Establishment and Founding History # JB Chemicals &amp; Pharmaceuticals Ltd. was established in 1976 by Mr. J. B. Mody.
Headquarters Location and Global Presence # The company’s headquarters are located in Mumbai, India. JB Pharma has a presence in India and exports its formulations to over 40 countries across the globe. Key markets include India, Russia, South Africa, and other emerging markets.">
  <meta property="og:locale" content="en_us">
  <meta property="og:type" content="article">
    <meta property="article:section" content="posts">
    <meta property="article:published_time" content="2024-07-26T19:23:35+00:00">
    <meta property="article:modified_time" content="2024-07-26T19:23:35+00:00">
    <meta property="article:tag" content="JB Chemicals & Pharmaceuticals Ltd.">
    <meta property="article:tag" content="JBCHEPHARM">
    <meta property="article:tag" content="Branded Medicines">
    <meta property="article:tag" content="Healthcare">
    <meta property="article:tag" content="Mid Cap">
    <meta property="article:tag" content="Annual Report">













<link rel="stylesheet" href="/assets/combined.min.83aead7461ea8e7fcfbb79b8c9400e1ec33efe08796484ba7a94d30f7b4923a8.css" media="all">




      <script async src="https://www.googletagmanager.com/gtag/js?id=G-T7PH4WNH24"></script>
      <script>
        var doNotTrack = false;
        if ( false ) {
          var dnt = (navigator.doNotTrack || window.doNotTrack || navigator.msDoNotTrack);
          var doNotTrack = (dnt == "1" || dnt == "yes");
        }
        if (!doNotTrack) {
          window.dataLayer = window.dataLayer || [];
          function gtag(){dataLayer.push(arguments);}
          gtag('js', new Date());
          gtag('config', 'G-T7PH4WNH24');
        }
      </script>




<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-3609399560636561" crossorigin="anonymous"></script>
</head>







<body class="light">
  <div class="content">
    <header>
      

<div class="header">

    
    <div id="search"></div>
</div>

    </header>
    <main class="main">
      





<div class="breadcrumbs">
    
    <a href="/">Home</a>
    <span class="breadcrumbs-separator"> > </span>
    
    <a href="/posts/">Posts</a>
    <span class="breadcrumbs-separator"> > </span>
    
    <a class="breadcrumbs-current" href="/posts/j-b-chemicals--pharmaceuticals-ltdannual-report-2023-24-analysis/">J B Chemicals &amp; Pharmaceuticals Ltd:Annual Report 2023-24 Analysis</a>
</div>



<div >

  <div class="single-intro-container">

    

    <h1 class="single-title" data-pagefind-body>J B Chemicals &amp; Pharmaceuticals Ltd:Annual Report 2023-24 Analysis</h1>
    

    

    <p class="single-readtime">
      
      
      
      <time datetime="2024-07-26T19:23:35&#43;00:00">July 26, 2024</time>
      

      
      &nbsp; · &nbsp;
      21 min read
      
    </p>

  </div>

  

  
  

  <div class="single-tags">
    
    <span>
      <a href="https://reports.muthu.co/tags/jb-chemicals--pharmaceuticals-ltd./">#JB Chemicals &amp; Pharmaceuticals Ltd.</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/jbchepharm/">#JBCHEPHARM</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/branded-medicines/">#Branded Medicines</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/healthcare/">#Healthcare</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/mid-cap/">#Mid Cap</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/annual-report/">#Annual Report</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/2023-24/">#2023-24</a>
    </span>
    
    
  </div>

  
  

  

  
  <aside class="toc">
    <p><strong>Table of contents</strong></p>
    <nav id="TableOfContents">
  <ul>
    <li><a href="#jb-chemicals--pharmaceuticals-ltd-a-comprehensive-overview">JB Chemicals &amp; Pharmaceuticals Ltd.: A Comprehensive Overview</a>
      <ul>
        <li><a href="#about-the-company">About the Company</a></li>
        <li><a href="#their-products">Their Products</a></li>
        <li><a href="#primary-customers">Primary Customers</a></li>
        <li><a href="#major-competitors">Major Competitors</a></li>
        <li><a href="#future-outlook">Future Outlook</a></li>
      </ul>
    </li>
    <li><a href="#comprehensive-performance-overview">Comprehensive Performance Overview</a>
      <ul>
        <li><a href="#key-financial-metrics-3-year-trend-analysis">Key Financial Metrics: 3-Year Trend Analysis</a></li>
        <li><a href="#business-segment-performance">Business Segment Performance</a></li>
        <li><a href="#major-strategic-initiatives-and-progress">Major Strategic Initiatives and Progress</a></li>
        <li><a href="#risk-landscape-changes">Risk Landscape Changes</a></li>
        <li><a href="#esg-initiatives-and-metrics">ESG Initiatives and Metrics</a></li>
      </ul>
    </li>
    <li><a href="#jb-chemicals--pharmaceuticals-limited---financial-position-analysis">J.B. Chemicals &amp; Pharmaceuticals Limited - Financial Position Analysis</a>
      <ul>
        <li><a href="#balance-sheet-analysis-3-year-comparative">Balance Sheet Analysis (3-Year Comparative)</a></li>
        <li><a href="#significant-year-over-year-changes-10">Significant Year-over-Year Changes (&gt;10%)</a></li>
        <li><a href="#working-capital-trends">Working Capital Trends</a></li>
        <li><a href="#asset-quality-metrics">Asset Quality Metrics</a></li>
        <li><a href="#debt-structure-and-maturity-profile">Debt Structure and Maturity Profile</a></li>
        <li><a href="#off-balance-sheet-items">Off-Balance Sheet Items</a></li>
      </ul>
    </li>
    <li><a href="#operating-performance-analysis-of-jb-chemicals--pharmaceuticals-limited">Operating Performance Analysis of J.B. Chemicals &amp; Pharmaceuticals Limited</a>
      <ul>
        <li><a href="#revenue-breakdown-by-segmentgeography-with-growth-rates">Revenue Breakdown by Segment/Geography with Growth Rates</a></li>
        <li><a href="#cost-structure-analysis">Cost Structure Analysis</a></li>
        <li><a href="#margin-analysis-consolidated">Margin Analysis (Consolidated)</a></li>
        <li><a href="#operating-leverage">Operating Leverage</a></li>
        <li><a href="#gaap-vs-non-gaap-reconciliation">GAAP vs. Non-GAAP Reconciliation</a></li>
        <li><a href="#eps-analysis-basicdiluted">EPS Analysis (Basic/Diluted)</a></li>
      </ul>
    </li>
    <li><a href="#cash-management">Cash Management</a>
      <ul>
        <li><a href="#cash-flow-and-liquidity-analysis">Cash Flow and Liquidity Analysis</a></li>
        <li><a href="#working-capital-management-efficiency">Working Capital Management Efficiency</a></li>
        <li><a href="#capex-analysis-by-segment">Capex Analysis by Segment</a></li>
        <li><a href="#dividend-and-share-buyback-trends">Dividend and Share Buyback Trends</a></li>
        <li><a href="#debt-service-coverage">Debt Service Coverage</a></li>
        <li><a href="#liquidity-position">Liquidity Position</a></li>
      </ul>
    </li>
    <li><a href="#financial-analysis-of-jb-chemicals--pharmaceuticals-limited">Financial Analysis of J.B. Chemicals &amp; Pharmaceuticals Limited</a>
      <ul>
        <li><a href="#profitability-ratios-3-year-trends---consolidated">Profitability Ratios (3-Year Trends - Consolidated)</a></li>
        <li><a href="#liquidity-metrics-consolidated">Liquidity Metrics (Consolidated)</a></li>
        <li><a href="#efficiency-ratios-consolidated">Efficiency Ratios (Consolidated)</a></li>
        <li><a href="#leverage-metrics-consolidated">Leverage Metrics (Consolidated)</a></li>
        <li><a href="#working-capital-ratios">Working Capital Ratios</a></li>
        <li><a href="#comparison-with-industry-averages-and-significant-deviations">Comparison with Industry Averages and Significant Deviations</a></li>
      </ul>
    </li>
    <li><a href="#business-segments-performance-analysis">Business Segments Performance Analysis</a>
      <ul>
        <li><a href="#revenue-and-profitability-metrics-with-growth-rates">Revenue and Profitability Metrics with Growth Rates</a></li>
        <li><a href="#market-share-and-competitive-position">Market Share and Competitive Position</a></li>
        <li><a href="#key-productsservices-performance">Key Products/Services Performance</a></li>
        <li><a href="#geographic-distribution-and-market-penetration">Geographic Distribution and Market Penetration</a></li>
        <li><a href="#segment-wise-capex-and-roic">Segment-wise CAPEX and ROIC</a></li>
        <li><a href="#operational-efficiency-metrics">Operational Efficiency Metrics</a></li>
        <li><a href="#growth-initiatives-and-challenges">Growth Initiatives and Challenges</a></li>
      </ul>
    </li>
    <li><a href="#forward-outlook-jb-chemicals--pharmaceuticals-limited-analysis">Forward Outlook: J.B. Chemicals &amp; Pharmaceuticals Limited Analysis</a>
      <ul>
        <li><a href="#management-guidance-and-assumptions">Management Guidance and Assumptions</a></li>
        <li><a href="#market-growth-forecasts">Market Growth Forecasts</a></li>
        <li><a href="#planned-strategic-initiatives">Planned Strategic Initiatives</a></li>
        <li><a href="#capital-expenditure-plans">Capital Expenditure Plans</a></li>
        <li><a href="#efficiency-improvement-targets">Efficiency Improvement Targets</a></li>
        <li><a href="#potential-challenges-and-opportunities">Potential Challenges and Opportunities</a></li>
        <li><a href="#scenario-analysis-and-sensitivity-to-key-assumptions">Scenario Analysis and Sensitivity to Key Assumptions</a></li>
      </ul>
    </li>
    <li><a href="#audit-and-compliance-analysis">Audit and Compliance Analysis</a>
      <ul>
        <li><a href="#auditors-opinion-and-qualifications">Auditor&rsquo;s Opinion and Qualifications</a></li>
        <li><a href="#key-accounting-policies-and-changes">Key Accounting Policies and Changes</a></li>
        <li><a href="#internal-control-effectiveness">Internal Control Effectiveness</a></li>
        <li><a href="#regulatory-compliance-status">Regulatory Compliance Status</a></li>
        <li><a href="#legal-proceedings-and-their-potential-impact">Legal Proceedings and Their Potential Impact</a></li>
        <li><a href="#related-party-transactions">Related Party Transactions</a></li>
        <li><a href="#subsequent-events">Subsequent Events</a></li>
        <li><a href="#accounting-quality-analysis">Accounting Quality Analysis</a></li>
        <li><a href="#regulatory-risk-assessment">Regulatory Risk Assessment</a></li>
      </ul>
    </li>
  </ul>
</nav>
  </aside>
  

  

  <div class="single-content">
    <h2 class="heading" id="jb-chemicals--pharmaceuticals-ltd-a-comprehensive-overview">
  JB Chemicals &amp; Pharmaceuticals Ltd.: A Comprehensive Overview
  <a class="anchor" href="#jb-chemicals--pharmaceuticals-ltd-a-comprehensive-overview">#</a>
</h2>
<h3 class="heading" id="about-the-company">
  About the Company
  <a class="anchor" href="#about-the-company">#</a>
</h3>
<h4 class="heading" id="year-of-establishment-and-founding-history">
  Year of Establishment and Founding History
  <a class="anchor" href="#year-of-establishment-and-founding-history">#</a>
</h4>
<p>JB Chemicals &amp; Pharmaceuticals Ltd. was established in <strong>1976</strong> by Mr. J. B. Mody.</p>
<h4 class="heading" id="headquarters-location-and-global-presence">
  Headquarters Location and Global Presence
  <a class="anchor" href="#headquarters-location-and-global-presence">#</a>
</h4>
<p>The company&rsquo;s headquarters are located in <strong>Mumbai, India</strong>. JB Pharma has a presence in India and exports its formulations to over 40 countries across the globe. Key markets include India, Russia, South Africa, and other emerging markets.</p>
<h4 class="heading" id="company-vision-and-mission">
  Company Vision and Mission
  <a class="anchor" href="#company-vision-and-mission">#</a>
</h4>
<ul>
<li><strong>Vision:</strong> To be a leading global healthcare provider improving lives through innovative and affordable solutions.</li>
<li><strong>Mission:</strong> Not publicly available.</li>
</ul>
<h4 class="heading" id="key-milestones-in-their-growth-journey">
  Key Milestones in Their Growth Journey
  <a class="anchor" href="#key-milestones-in-their-growth-journey">#</a>
</h4>
<ul>
<li><strong>1976:</strong> Incorporated as JB Chemicals &amp; Pharmaceuticals Ltd.</li>
<li><strong>1985:</strong> Launched Rantac, an anti-ulcerant drug, which became a significant revenue generator.</li>
<li><strong>2011:</strong> Sold its over-the-counter (OTC) brands business to Johnson &amp; Johnson for ₹3,100 crore.</li>
<li><strong>2020:</strong> Acquired a portfolio of brands from Sanzyme Private Limited.</li>
<li><strong>2020:</strong> Acquired a portfolio of brands from Novartis AG.</li>
</ul>
<h4 class="heading" id="stock-exchange-listing-details-and-market-capitalization">
  Stock Exchange Listing Details and Market Capitalization
  <a class="anchor" href="#stock-exchange-listing-details-and-market-capitalization">#</a>
</h4>
<p>JB Chemicals &amp; Pharmaceuticals Ltd. is listed on the <strong>National Stock Exchange (NSE)</strong> and the <strong>Bombay Stock Exchange (BSE)</strong>.</p>
<h4 class="heading" id="recent-financial-performance-highlights">
  Recent Financial Performance Highlights
  <a class="anchor" href="#recent-financial-performance-highlights">#</a>
</h4>
<ul>
<li>JB Pharma reported strong results for FY24, with revenues growing 12.2% to ₹3,459 crore and EBITDA increasing 18.4% to ₹1,017 crore.</li>
</ul>
<h4 class="heading" id="management-team-and-leadership-structure">
  Management Team and Leadership Structure
  <a class="anchor" href="#management-team-and-leadership-structure">#</a>
</h4>
<ul>
<li><strong>Nikhil Chopra:</strong> CEO &amp; Whole-time Director</li>
</ul>
<h4 class="heading" id="any-notable-awards-or-recognitions">
  Any Notable Awards or Recognitions
  <a class="anchor" href="#any-notable-awards-or-recognitions">#</a>
</h4>
<ul>
<li>Consistently recognized for its strong financial performance and corporate governance practices.</li>
</ul>
<h3 class="heading" id="their-products">
  Their Products
  <a class="anchor" href="#their-products">#</a>
</h3>
<h4 class="heading" id="complete-product-portfolio-with-categories">
  Complete Product Portfolio with Categories
  <a class="anchor" href="#complete-product-portfolio-with-categories">#</a>
</h4>
<p>JB Pharma&rsquo;s product portfolio covers various therapeutic areas, including:</p>
<ul>
<li><strong>Cardiology:</strong> Azmarda, Cilacar, Nicardia Retard</li>
<li><strong>Gastroenterology:</strong> Rantac, Metrogyl</li>
<li><strong>Respiratory:</strong> Dilosyn, Alex Cough Syrup</li>
<li><strong>Dermatology:</strong> Oxerute</li>
</ul>
<h4 class="heading" id="flagship-or-signature-product-lines">
  Flagship or Signature Product Lines
  <a class="anchor" href="#flagship-or-signature-product-lines">#</a>
</h4>
<ul>
<li><strong>Rantac:</strong> A well-known brand in the anti-ulcerant segment.</li>
<li><strong>Cilacar:</strong> Used in the treatment of hypertension</li>
</ul>
<h4 class="heading" id="key-technological-innovations-or-patents">
  Key Technological Innovations or Patents
  <a class="anchor" href="#key-technological-innovations-or-patents">#</a>
</h4>
<p>Focus is on developing and marketing formulations with established APIs. While not heavily focused on novel molecule discovery, they continually improve existing formulations and delivery mechanisms.</p>
<h4 class="heading" id="manufacturing-facilities-and-production-capacity">
  Manufacturing Facilities and Production Capacity
  <a class="anchor" href="#manufacturing-facilities-and-production-capacity">#</a>
</h4>
<p>JB Pharma operates several manufacturing facilities in India. Details on exact production capacity are not readily available in the public domain.</p>
<h4 class="heading" id="quality-certifications-and-standards">
  Quality Certifications and Standards
  <a class="anchor" href="#quality-certifications-and-standards">#</a>
</h4>
<p>JB Pharma maintains high quality standards across its manufacturing facilities, complying with:</p>
<ul>
<li>Good Manufacturing Practices (GMP)</li>
<li>WHO-GMP</li>
</ul>
<h4 class="heading" id="any-unique-selling-propositions-or-technological-advantages">
  Any Unique Selling Propositions or Technological Advantages
  <a class="anchor" href="#any-unique-selling-propositions-or-technological-advantages">#</a>
</h4>
<ul>
<li>Strong brand recall in key therapeutic areas.</li>
<li>Focus on affordability and accessibility of medicines.</li>
</ul>
<h4 class="heading" id="recent-product-launches-or-rd-initiatives">
  Recent Product Launches or R&amp;D Initiatives
  <a class="anchor" href="#recent-product-launches-or-rd-initiatives">#</a>
</h4>
<ul>
<li>JB Pharma continues to launch new products and line extensions within its existing therapeutic areas.</li>
</ul>
<h3 class="heading" id="primary-customers">
  Primary Customers
  <a class="anchor" href="#primary-customers">#</a>
</h3>
<h4 class="heading" id="target-industries-and-sectors">
  Target Industries and Sectors
  <a class="anchor" href="#target-industries-and-sectors">#</a>
</h4>
<p>Healthcare, Pharmaceuticals, Retail Pharmacies, Hospitals, Clinics.</p>
<h4 class="heading" id="geographic-markets-domestic-vs-international">
  Geographic Markets (Domestic vs. International)
  <a class="anchor" href="#geographic-markets-domestic-vs-international">#</a>
</h4>
<ul>
<li><strong>Domestic (India):</strong> A significant portion of its revenue comes from the Indian market.</li>
<li><strong>International:</strong> Exports to over 40 countries, including Russia, South Africa, and other emerging markets.</li>
</ul>
<h4 class="heading" id="distribution-network-and-sales-channels">
  Distribution Network and Sales Channels
  <a class="anchor" href="#distribution-network-and-sales-channels">#</a>
</h4>
<ul>
<li>Well-established distribution network across India and in international markets.</li>
<li>Uses a combination of direct sales teams and distribution partners.</li>
</ul>
<h3 class="heading" id="major-competitors">
  Major Competitors
  <a class="anchor" href="#major-competitors">#</a>
</h3>
<h4 class="heading" id="direct-competitors-in-india-and-globally">
  Direct Competitors in India and Globally
  <a class="anchor" href="#direct-competitors-in-india-and-globally">#</a>
</h4>
<ul>
<li>Sun Pharmaceutical Industries Ltd.</li>
<li>Cipla Ltd.</li>
<li>Dr. Reddy&rsquo;s Laboratories Ltd.</li>
<li>Lupin Ltd.</li>
<li>Zydus Lifesciences Ltd.</li>
<li>Glenmark Pharmaceuticals Ltd.</li>
<li>Torrent Pharmaceuticals Ltd.</li>
</ul>
<h4 class="heading" id="competitive-advantages-and-disadvantages">
  Competitive Advantages and Disadvantages
  <a class="anchor" href="#competitive-advantages-and-disadvantages">#</a>
</h4>
<ul>
<li><strong>Advantages:</strong> Strong brand recognition, well-established distribution network, focus on affordability.</li>
<li><strong>Disadvantages:</strong> Faces intense competition from larger players, vulnerability to pricing pressures, dependent on mature brands in some segments.</li>
</ul>
<h4 class="heading" id="how-they-differentiate-from-competitors">
  How They Differentiate From Competitors
  <a class="anchor" href="#how-they-differentiate-from-competitors">#</a>
</h4>
<ul>
<li>Focus on specific therapeutic areas and maintaining leadership positions within those segments.</li>
<li>Emphasis on affordability and accessibility of medicines in emerging markets.</li>
</ul>
<h4 class="heading" id="market-positioning-strategy">
  Market Positioning Strategy
  <a class="anchor" href="#market-positioning-strategy">#</a>
</h4>
<p>JB Pharma positions itself as a provider of quality and affordable medicines, particularly in key therapeutic areas like cardiology, gastroenterology, and respiratory.</p>
<h3 class="heading" id="future-outlook">
  Future Outlook
  <a class="anchor" href="#future-outlook">#</a>
</h3>
<h4 class="heading" id="expansion-plans-or-growth-strategy">
  Expansion Plans or Growth Strategy
  <a class="anchor" href="#expansion-plans-or-growth-strategy">#</a>
</h4>
<ul>
<li>Focus on strengthening its presence in India and key international markets.</li>
<li>In-licensing and acquisitions to expand its product portfolio.</li>
<li>Investing in R&amp;D for new formulations and line extensions.</li>
</ul>
<h4 class="heading" id="sustainability-initiatives-or-esg-commitments">
  Sustainability Initiatives or ESG Commitments
  <a class="anchor" href="#sustainability-initiatives-or-esg-commitments">#</a>
</h4>
<ul>
<li>Details regarding specific sustainability initiatives are not readily available in the public domain.</li>
</ul>
<h4 class="heading" id="industry-trends-affecting-their-business">
  Industry Trends Affecting Their Business
  <a class="anchor" href="#industry-trends-affecting-their-business">#</a>
</h4>
<ul>
<li>Increasing healthcare expenditure in emerging markets.</li>
<li>Rising incidence of chronic diseases.</li>
<li>Growing demand for affordable medicines.</li>
<li>Stringent regulatory requirements.</li>
</ul>
<h4 class="heading" id="long-term-vision-and-strategic-goals">
  Long-Term Vision and Strategic Goals
  <a class="anchor" href="#long-term-vision-and-strategic-goals">#</a>
</h4>
<p>JB Pharma aims to become a leading global healthcare provider by focusing on innovation, affordability, and accessibility of medicines.</p>
<hr>
<h2 class="heading" id="comprehensive-performance-overview">
  Comprehensive Performance Overview
  <a class="anchor" href="#comprehensive-performance-overview">#</a>
</h2>
<h3 class="heading" id="key-financial-metrics-3-year-trend-analysis">
  Key Financial Metrics: 3-Year Trend Analysis
  <a class="anchor" href="#key-financial-metrics-3-year-trend-analysis">#</a>
</h3>
<ul>
<li>Revenue demonstrated a 3-year Compound Annual Growth Rate (CAGR) of 19%, reaching INR 3484 crores in FY24 from INR 2043 crores in FY21, including contributions from acquisitions.</li>
<li>Operating EBITDA also showed a 3-year CAGR of 19%, increasing to INR 939 crores in FY24 from INR 560 crores in FY21.</li>
<li>Net Working Capital improved, decreasing to 87 days in FY24 from 98 days in FY21.</li>
<li>Operating Cash Flows as a percentage of Operating EBITDA significantly improved to 85% in FY24 from 56% in FY21.</li>
<li>Consolidated EPS increased to 35.66 in FY 2024 From 26.50 in FY 2023.</li>
</ul>
<h3 class="heading" id="business-segment-performance">
  Business Segment Performance
  <a class="anchor" href="#business-segment-performance">#</a>
</h3>
<ul>
<li>The domestic formulations business exhibited a 16% growth, reaching INR 189,791 lakhs in FY24, outperforming the Indian Pharmaceuticals Market (IPM) growth.</li>
<li>The international business grew by 5%, reaching INR 158,627 lakhs, affected by strategic decisions in the South Africa business, offset by growth in the CDMO and other international formulation businesses.</li>
<li>The CDMO business grew by 6%, reaching INR 43,185 lakhs.</li>
<li>API business recorded sales of INR 8,588 lakhs in FY24, a decrease compared to INR 9,359 lakhs in FY23.</li>
</ul>
<h3 class="heading" id="major-strategic-initiatives-and-progress">
  Major Strategic Initiatives and Progress
  <a class="anchor" href="#major-strategic-initiatives-and-progress">#</a>
</h3>
<ul>
<li>Realignment of the Go-To-Market (GTM) model has improved field force productivity to INR 6.8 lakhs per person per month (PCPM).</li>
<li>The strategic focus on chronic therapies resulted in 14% growth, outpacing the IPM chronic segment growth of 10%.</li>
<li>Five major brands (Cilacar, Rantac, Metrogyl, Cilacar-T, and Nicardia) now rank among the top 150 IPM brands.</li>
<li>Acquisition of a portfolio of 10 ophthalmology brands from Novartis Innovative Therapies AG has solidified JB Pharma&rsquo;s position in the ophthalmology segment.</li>
</ul>
<h3 class="heading" id="risk-landscape-changes">
  Risk Landscape Changes
  <a class="anchor" href="#risk-landscape-changes">#</a>
</h3>
<ul>
<li>The primary risks identified are those common to the pharmaceutical industry, including regulatory risks, exchange risks, cyber risks, and commercial and business-related risks, with a strong risk mitigation plan deployed and regularly reviewed.</li>
</ul>
<h3 class="heading" id="esg-initiatives-and-metrics">
  ESG Initiatives and Metrics
  <a class="anchor" href="#esg-initiatives-and-metrics">#</a>
</h3>
<ul>
<li>Total energy consumption within the organization reduced by 9%.</li>
<li>Scope 1 and Scope 2 emissions reduced by 16.67% in FY24 compared to FY23.</li>
<li>Renewable energy sources constitute 13% of total energy demand.</li>
<li>Water consumption intensity per rupee of turnover reduced by 9.4%.</li>
<li>All manufacturing plants maintain Zero Liquid Discharge status.</li>
<li>Female representation is at 11% of the permanent workforce.</li>
<li>CSR initiatives positively impacted lives in areas of healthcare, education, and environment.</li>
</ul>
<hr>
<h4 class="heading" id="detailed-analysis">
  Detailed Analysis
  <a class="anchor" href="#detailed-analysis">#</a>
</h4>
<hr>
<h2 class="heading" id="jb-chemicals--pharmaceuticals-limited---financial-position-analysis">
  J.B. Chemicals &amp; Pharmaceuticals Limited - Financial Position Analysis
  <a class="anchor" href="#jb-chemicals--pharmaceuticals-limited---financial-position-analysis">#</a>
</h2>
<h3 class="heading" id="balance-sheet-analysis-3-year-comparative">
  Balance Sheet Analysis (3-Year Comparative)
  <a class="anchor" href="#balance-sheet-analysis-3-year-comparative">#</a>
</h3>
<p>Comparative financial data for the past three fiscal years (Consolidated, ₹ in lakhs):</p>
<table>
  <thead>
      <tr>
          <th style="text-align: left">Particulars</th>
          <th style="text-align: right">FY 2023-24</th>
          <th style="text-align: right">FY 2022-23</th>
          <th style="text-align: right">FY 2021-22</th>
      </tr>
  </thead>
  <tbody>
      <tr>
          <td style="text-align: left"><strong>Assets</strong></td>
          <td style="text-align: right"></td>
          <td style="text-align: right"></td>
          <td style="text-align: right"></td>
      </tr>
      <tr>
          <td style="text-align: left">Non-Current Assets</td>
          <td style="text-align: right">214,078.18</td>
          <td style="text-align: right">202,583.76</td>
          <td style="text-align: right">132,640.70</td>
      </tr>
      <tr>
          <td style="text-align: left">Current Assets</td>
          <td style="text-align: right">185,334.53</td>
          <td style="text-align: right">152,803.30</td>
          <td style="text-align: right">87,741.39</td>
      </tr>
      <tr>
          <td style="text-align: left"><strong>Total Assets</strong></td>
          <td style="text-align: right"><strong>399,412.71</strong></td>
          <td style="text-align: right"><strong>355,387.06</strong></td>
          <td style="text-align: right"><strong>220,382.09</strong></td>
      </tr>
      <tr>
          <td style="text-align: left"><strong>Liabilities</strong></td>
          <td style="text-align: right"></td>
          <td style="text-align: right"></td>
          <td style="text-align: right"></td>
      </tr>
      <tr>
          <td style="text-align: left">Non-Current Liabilities</td>
          <td style="text-align: right">20,257.17</td>
          <td style="text-align: right">51,906.91</td>
          <td style="text-align: right">7,955.82</td>
      </tr>
      <tr>
          <td style="text-align: left">Current Liabilities</td>
          <td style="text-align: right">86,822.61</td>
          <td style="text-align: right">55,444.93</td>
          <td style="text-align: right">23,268.59</td>
      </tr>
      <tr>
          <td style="text-align: left"><strong>Total Liabilities</strong></td>
          <td style="text-align: right"><strong>107,079.78</strong></td>
          <td style="text-align: right"><strong>107,351.84</strong></td>
          <td style="text-align: right"><strong>31,224.41</strong></td>
      </tr>
      <tr>
          <td style="text-align: left"><strong>Equity</strong></td>
          <td style="text-align: right"></td>
          <td style="text-align: right"></td>
          <td style="text-align: right"></td>
      </tr>
      <tr>
          <td style="text-align: left">Equity Share Capital</td>
          <td style="text-align: right">1,551.95</td>
          <td style="text-align: right">1,547.55</td>
          <td style="text-align: right">1,545.64</td>
      </tr>
      <tr>
          <td style="text-align: left">Other Equity</td>
          <td style="text-align: right">290,780.98</td>
          <td style="text-align: right">246,487.67</td>
          <td style="text-align: right">207,612.04</td>
      </tr>
      <tr>
          <td style="text-align: left"><strong>Total Equity</strong></td>
          <td style="text-align: right"><strong>292,332.93</strong></td>
          <td style="text-align: right"><strong>248,035.22</strong></td>
          <td style="text-align: right"><strong>220,382.08</strong></td>
      </tr>
  </tbody>
</table>
<h3 class="heading" id="significant-year-over-year-changes-10">
  Significant Year-over-Year Changes (&gt;10%)
  <a class="anchor" href="#significant-year-over-year-changes-10">#</a>
</h3>
<ul>
<li><strong>Non-Current Assets:</strong> Increased by 5.67% mainly due to Increases in Capital work-in-progress, Intangible assets and investments.</li>
<li><strong>Current Assets:</strong> Increased by 21.29%, mainly driven by increases in inventories, trade receivables, and investments.</li>
<li><strong>Non-Current Liabilities:</strong> Decreased by 61%, primarily due to significant loan repayments for brand acquisition, and reduction of Lease liabilities.</li>
<li><strong>Current Liabilities:</strong> Increased by 56.6%, primarily due to rise in borrowings and trade payables.</li>
<li><strong>Other Equity:</strong> Increased by 17.98% due to profit for the year and share-based payment expenses.</li>
</ul>
<h3 class="heading" id="working-capital-trends">
  Working Capital Trends
  <a class="anchor" href="#working-capital-trends">#</a>
</h3>
<p>Working capital trends (Consolidated, ₹ in lakhs):</p>
<table>
  <thead>
      <tr>
          <th style="text-align: left">Particulars</th>
          <th style="text-align: right">FY 2023-24</th>
          <th style="text-align: right">FY 2022-23</th>
          <th style="text-align: left">Change</th>
      </tr>
  </thead>
  <tbody>
      <tr>
          <td style="text-align: left">Current Assets</td>
          <td style="text-align: right">185,334.53</td>
          <td style="text-align: right">152,803.30</td>
          <td style="text-align: left">+21.29%</td>
      </tr>
      <tr>
          <td style="text-align: left">Current Liabilities</td>
          <td style="text-align: right">86,822.61</td>
          <td style="text-align: right">55,444.93</td>
          <td style="text-align: left">+56.6%</td>
      </tr>
      <tr>
          <td style="text-align: left"><strong>Net Working Capital</strong></td>
          <td style="text-align: right"><strong>98,511.92</strong></td>
          <td style="text-align: right"><strong>97,358.37</strong></td>
          <td style="text-align: left"><strong>+1.19%</strong></td>
      </tr>
      <tr>
          <td style="text-align: left">Current Ratio</td>
          <td style="text-align: right">2.13</td>
          <td style="text-align: right">2.76</td>
          <td style="text-align: left">(22.82%)</td>
      </tr>
  </tbody>
</table>
<ul>
<li>The Current ratio decreased significantly, although it remains healthy above 2, the increase in current liabilities (particularly borrowings) outpaced the rise in current assets.</li>
</ul>
<h3 class="heading" id="asset-quality-metrics">
  Asset Quality Metrics
  <a class="anchor" href="#asset-quality-metrics">#</a>
</h3>
<table>
  <thead>
      <tr>
          <th style="text-align: left">Particulars</th>
          <th style="text-align: right">FY 2023-24</th>
          <th style="text-align: right">FY 2022-23</th>
      </tr>
  </thead>
  <tbody>
      <tr>
          <td style="text-align: left">Inventory Turnover Ratio</td>
          <td style="text-align: right">2.62</td>
          <td style="text-align: right">2.81</td>
      </tr>
      <tr>
          <td style="text-align: left">Trade Receivable Turnover Ratio</td>
          <td style="text-align: right">5.52</td>
          <td style="text-align: right">5.57</td>
      </tr>
  </tbody>
</table>
<p><em>Asset Quality is slightly affected.</em></p>
<h3 class="heading" id="debt-structure-and-maturity-profile">
  Debt Structure and Maturity Profile
  <a class="anchor" href="#debt-structure-and-maturity-profile">#</a>
</h3>
<table>
  <thead>
      <tr>
          <th style="text-align: left">Particulars</th>
          <th style="text-align: right">As at March 31, 2024</th>
          <th style="text-align: right">As at March 31, 2023</th>
      </tr>
  </thead>
  <tbody>
      <tr>
          <td style="text-align: left"><strong>Secured Borrowings</strong></td>
          <td style="text-align: right"></td>
          <td style="text-align: right"></td>
      </tr>
      <tr>
          <td style="text-align: left">Term loans from banks (Non-current)</td>
          <td style="text-align: right">2,363.87</td>
          <td style="text-align: right">38,322.03</td>
      </tr>
      <tr>
          <td style="text-align: left">Term Loan (Current Maturities)</td>
          <td style="text-align: right">31,815.98</td>
          <td style="text-align: right">13,700.00</td>
      </tr>
      <tr>
          <td style="text-align: left">Export packing credit (Current)</td>
          <td style="text-align: right">-</td>
          <td style="text-align: right">671.00</td>
      </tr>
      <tr>
          <td style="text-align: left">Working Capital demand loan</td>
          <td style="text-align: right">1,534.25</td>
          <td style="text-align: right">2,130.80</td>
      </tr>
      <tr>
          <td style="text-align: left"><strong>Total Borrowings</strong></td>
          <td style="text-align: right"><strong>35,714.10</strong></td>
          <td style="text-align: right"><strong>54,823.83</strong></td>
      </tr>
      <tr>
          <td style="text-align: left"><strong>Debt-Equity Ratio</strong></td>
          <td style="text-align: right"><strong>0.12</strong></td>
          <td style="text-align: right"><strong>0.22</strong></td>
      </tr>
  </tbody>
</table>
<ul>
<li>The company significantly reduced its non-current borrowings but increased its short-term debt.</li>
<li>The debt-to-equity ratio improved significantly, indicating lower leverage.</li>
</ul>
<p><strong>Maturity Profile of Term Loans:</strong></p>
<ul>
<li>The provided data gives a current portion of long-term borrowings as ₹31,815.98 lakhs for FY24.</li>
<li>Details of loan structure and maturity periods for the remaining long-term borrowings is presented in the Notes.</li>
</ul>
<h3 class="heading" id="off-balance-sheet-items">
  Off-Balance Sheet Items
  <a class="anchor" href="#off-balance-sheet-items">#</a>
</h3>
<table>
  <thead>
      <tr>
          <th style="text-align: left">Item</th>
          <th style="text-align: right">As at March 31, 2024</th>
          <th style="text-align: right">As at March 31, 2023</th>
      </tr>
  </thead>
  <tbody>
      <tr>
          <td style="text-align: left">Letters of Credit</td>
          <td style="text-align: right">2,515.67</td>
          <td style="text-align: right">1,688.49</td>
      </tr>
      <tr>
          <td style="text-align: left">Guarantees issued by banks</td>
          <td style="text-align: right">6,797.80</td>
          <td style="text-align: right">5,961.90</td>
      </tr>
      <tr>
          <td style="text-align: left">Contingent liabilities</td>
          <td></td>
          <td></td>
      </tr>
      <tr>
          <td style="text-align: left">(Claims not acknowledged)</td>
          <td style="text-align: right">3,850.03</td>
          <td style="text-align: right">2,823.02</td>
      </tr>
  </tbody>
</table>
<ul>
<li>Contingent liabilities related to tax and other claims increased.</li>
<li>Letters of credit and bank guarantees are standard off-balance sheet items for a company involved in international trade.</li>
</ul>
<h2 class="heading" id="operating-performance-analysis-of-jb-chemicals--pharmaceuticals-limited">
  Operating Performance Analysis of J.B. Chemicals &amp; Pharmaceuticals Limited
  <a class="anchor" href="#operating-performance-analysis-of-jb-chemicals--pharmaceuticals-limited">#</a>
</h2>
<h3 class="heading" id="revenue-breakdown-by-segmentgeography-with-growth-rates">
  Revenue Breakdown by Segment/Geography with Growth Rates
  <a class="anchor" href="#revenue-breakdown-by-segmentgeography-with-growth-rates">#</a>
</h3>
<ul>
<li><strong>Domestic Formulations:</strong> FY24 revenue was ₹189,791 lakhs, a 16% growth YoY.</li>
<li><strong>International Formulations:</strong> FY24 revenue was ₹106,855 lakhs, growing 6% YoY. Excluding South Africa, the business grew by 12%</li>
<li><strong>CDMO Business:</strong> FY24 revenue was ₹43,185 lakhs, a 6% growth YoY.</li>
<li><strong>API Business:</strong> FY24 Revenue was ₹8,588 Lakhs, showing decline from ₹9,359 lakhs in FY23.</li>
<li><strong>Geographical Revenue (Consolidated):</strong>
<ul>
<li><strong>India:</strong> Contributed a major share. FY24 Domestic Formulation revenue was ₹189,791 lakhs.</li>
<li><strong>International:</strong> Contributed 46% of total revenue, with ₹158,627 lakhs in FY24, a 5% growth.</li>
</ul>
</li>
</ul>
<h3 class="heading" id="cost-structure-analysis">
  Cost Structure Analysis
  <a class="anchor" href="#cost-structure-analysis">#</a>
</h3>
<ul>
<li><strong>Cost of Materials Consumed:</strong> ₹81,604.51 lakhs in FY24 (Standalone), increased from ₹78,378.09 lakhs in FY23.</li>
<li><strong>Employee Benefit Expenses:</strong> ₹56,538.43 lakhs in FY24 (Standalone), up from ₹49,994.59 lakhs in FY23.</li>
<li><strong>Other expenses:</strong> ₹74,477.05 lakhs in FY24, increased from ₹68,279.67. Major contributors included sales promotion, freight, and transport.</li>
</ul>
<h3 class="heading" id="margin-analysis-consolidated">
  Margin Analysis (Consolidated)
  <a class="anchor" href="#margin-analysis-consolidated">#</a>
</h3>
<ul>
<li><strong>Gross Margin:</strong> Improved from 62.9% in FY23 to 66.1% in FY24.</li>
<li><strong>Operating EBITDA Margin (excl. ESOPs):</strong> Increased by 270 basis points to 27.0% in FY24 from 24.3% in FY23.</li>
<li><strong>Net Profit Margin:</strong> 15.86% in FY24, up from 13.02% in FY23.</li>
</ul>
<h3 class="heading" id="operating-leverage">
  Operating Leverage
  <a class="anchor" href="#operating-leverage">#</a>
</h3>
<ul>
<li>Improved Operational efficiencies with an improvement of Operating EBITDA, which is a signal that Fixed Costs have contributed to higher profits before interest and taxes.</li>
</ul>
<h3 class="heading" id="gaap-vs-non-gaap-reconciliation">
  GAAP vs. Non-GAAP Reconciliation
  <a class="anchor" href="#gaap-vs-non-gaap-reconciliation">#</a>
</h3>
<ul>
<li>The report uses Ind AS (Indian Accounting Standards), which are converged with IFRS. A reconciliation to another GAAP (like US GAAP) is not provided. However, &ldquo;Operating EBITDA&rdquo; is presented excluding ESOP costs, representing a non-GAAP measure, to showcase operational profitability.</li>
</ul>
<h3 class="heading" id="eps-analysis-basicdiluted">
  EPS Analysis (Basic/Diluted)
  <a class="anchor" href="#eps-analysis-basicdiluted">#</a>
</h3>
<ul>
<li><strong>Basic EPS (Standalone):</strong> ₹35.07 in FY24, increased from ₹25.15 in FY23.</li>
<li><strong>Diluted EPS (Standalone):</strong> ₹34.30 in FY24, increased from ₹24.85 in FY23.</li>
<li><strong>Basic EPS (Consolidated):</strong> ₹35.66 in FY24, increased from ₹26.50 in FY23.</li>
<li><strong>Diluted EPS (Consolidated):</strong> ₹34.85 in FY24, increased from ₹26.17 in FY23</li>
</ul>
<h2 class="heading" id="cash-management">
  Cash Management
  <a class="anchor" href="#cash-management">#</a>
</h2>
<h3 class="heading" id="cash-flow-and-liquidity-analysis">
  Cash Flow and Liquidity Analysis
  <a class="anchor" href="#cash-flow-and-liquidity-analysis">#</a>
</h3>
<h4 class="heading" id="operating-cash-flow-ocf">
  Operating Cash Flow (OCF)
  <a class="anchor" href="#operating-cash-flow-ocf">#</a>
</h4>
<p>FY24: ₹ 78,903.31 Lakhs; FY23: ₹ 62,864.40 Lakhs. The increase in OCF is primarily due to higher profit before tax, with positive adjustments for depreciation, finance costs, and share-based payment expenses.</p>
<h4 class="heading" id="investing-cash-flow-icf">
  Investing Cash Flow (ICF)
  <a class="anchor" href="#investing-cash-flow-icf">#</a>
</h4>
<p>FY24: ₹ (41,244.97) Lakhs; FY23: ₹ (95,588.38) Lakhs. Significant cash outflows were due to the purchase of property, plant, and equipment, and intangible assets, as well as the purchase of current investments.</p>
<h4 class="heading" id="free-cash-flow-fcf">
  Free Cash Flow (FCF)
  <a class="anchor" href="#free-cash-flow-fcf">#</a>
</h4>
<p>Using a simpler OCF - Capex calculation:</p>
<ul>
<li>FY24: ₹ 78,903.31 - ₹ 12,611.28 = ₹ 66,292.03 Lakhs</li>
<li>FY23: ₹ 62,864.40 - ₹ 7,246.13 = ₹ 55,618.27 Lakhs</li>
</ul>
<h3 class="heading" id="working-capital-management-efficiency">
  Working Capital Management Efficiency
  <a class="anchor" href="#working-capital-management-efficiency">#</a>
</h3>
<h4 class="heading" id="debtors-turnover-ratio">
  Debtors Turnover Ratio
  <a class="anchor" href="#debtors-turnover-ratio">#</a>
</h4>
<p>FY24: 5.52 times; FY23: 5.57 times, represents a minimal change.</p>
<h4 class="heading" id="inventory-turnover-ratio">
  Inventory Turnover Ratio
  <a class="anchor" href="#inventory-turnover-ratio">#</a>
</h4>
<p>FY24: 2.53 times; FY23: 2.78 times. A slight decrease in inventory turnover suggests a marginal decrease in efficiency.</p>
<h4 class="heading" id="trade-payables-turnover-ratio">
  Trade Payables Turnover Ratio
  <a class="anchor" href="#trade-payables-turnover-ratio">#</a>
</h4>
<ul>
<li>Consolidated FY24: 4.37 times; FY23: 5.18 times.</li>
<li>Standalone: FY24: 4.45 times; FY23: 5.27 times. Represents a decrease.</li>
</ul>
<h3 class="heading" id="capex-analysis-by-segment">
  Capex Analysis by Segment
  <a class="anchor" href="#capex-analysis-by-segment">#</a>
</h3>
<p>All Capital expenditure incurred during FY24 is on:</p>
<ul>
<li>(a) conservation of energy, technology absorbtion, ₹ 50 Lakhs at Panoli and ₹ 140 Lakhs in Daman and</li>
<li>(b) on Research and Development with ₹ 471.23 capital.</li>
</ul>
<h3 class="heading" id="dividend-and-share-buyback-trends">
  Dividend and Share Buyback Trends
  <a class="anchor" href="#dividend-and-share-buyback-trends">#</a>
</h3>
<h4 class="heading" id="dividend">
  Dividend
  <a class="anchor" href="#dividend">#</a>
</h4>
<ul>
<li>Interim dividend of ₹ 5.50 per share (550%) was paid in FY24.</li>
<li>A final dividend of ₹ 6.75 per share (675%) is proposed for FY24.</li>
<li>The combined dividend payout for FY24 is projected to be ₹ 19,009.42 Lakhs.</li>
<li>FY23 saw an interim dividend of ₹ 8.50 and a final of ₹ 9.25. After the share split, dividend per share is ₹ 12.25.</li>
</ul>
<h4 class="heading" id="share-buyback">
  Share Buyback
  <a class="anchor" href="#share-buyback">#</a>
</h4>
<p>No share buybacks were mentioned for FY23-24.</p>
<h3 class="heading" id="debt-service-coverage">
  Debt Service Coverage
  <a class="anchor" href="#debt-service-coverage">#</a>
</h3>
<h4 class="heading" id="debt-service-coverage-ratio">
  Debt Service Coverage Ratio
  <a class="anchor" href="#debt-service-coverage-ratio">#</a>
</h4>
<p>Consolidated: FY24: 1.91 times; FY23: 2.97 times. This indicates higher debt repayment in FY24.</p>
<h3 class="heading" id="liquidity-position">
  Liquidity Position
  <a class="anchor" href="#liquidity-position">#</a>
</h3>
<h4 class="heading" id="current-ratio">
  Current Ratio
  <a class="anchor" href="#current-ratio">#</a>
</h4>
<ul>
<li>Consolidated: FY24: 2.09:1; FY23: 2.64:1.</li>
<li>Standalone: FY24: 2.10:1; FY23: 2.65:1.
Decrease indicates a small reduction in short-term liquidity.</li>
</ul>
<h2 class="heading" id="financial-analysis-of-jb-chemicals--pharmaceuticals-limited">
  Financial Analysis of J.B. Chemicals &amp; Pharmaceuticals Limited
  <a class="anchor" href="#financial-analysis-of-jb-chemicals--pharmaceuticals-limited">#</a>
</h2>
<h3 class="heading" id="profitability-ratios-3-year-trends---consolidated">
  Profitability Ratios (3-Year Trends - Consolidated)
  <a class="anchor" href="#profitability-ratios-3-year-trends---consolidated">#</a>
</h3>
<ul>
<li><strong>Return on Equity (ROE):</strong> FY24: 18.92%, FY23: 16.53%, FY21: 23.55%. ROE increased, indicating improved profitability relative to shareholder investment.</li>
<li><strong>Operating EBITDA Margin (excl. ESOP Cost):</strong> FY24: 27.0%, FY23: 24.29%, FY21: 27.4%. Operating profitability improved significantly.</li>
<li><strong>Net Profit Margin:</strong> FY24: 15.86%, FY23: 13.02%, FY21: 22.3%. Net profit margin has also increased, demonstrating better conversion of revenue to profit.</li>
</ul>
<h3 class="heading" id="liquidity-metrics-consolidated">
  Liquidity Metrics (Consolidated)
  <a class="anchor" href="#liquidity-metrics-consolidated">#</a>
</h3>
<ul>
<li><strong>Current Ratio:</strong> FY24: 2.09, FY23: 2.64. A decrease, but still indicates a healthy ability to meet short-term obligations, though slightly less buffer than the previous year.</li>
</ul>
<h3 class="heading" id="efficiency-ratios-consolidated">
  Efficiency Ratios (Consolidated)
  <a class="anchor" href="#efficiency-ratios-consolidated">#</a>
</h3>
<ul>
<li><strong>Inventory Turnover Ratio:</strong> FY24: 2.53, FY23: 2.78. A slight decrease, indicating a potentially slower inventory movement.</li>
<li><strong>Trade Receivables Turnover Ratio:</strong> FY24: 5.52, FY23: 5.57. Remained relatively stable.</li>
</ul>
<h3 class="heading" id="leverage-metrics-consolidated">
  Leverage Metrics (Consolidated)
  <a class="anchor" href="#leverage-metrics-consolidated">#</a>
</h3>
<ul>
<li><strong>Debt-to-Equity Ratio:</strong> FY24: 0.129:1, FY23: 0.231:1. Decreased, showing reduced reliance on debt financing.</li>
<li><strong>Interest Coverage Ratio:</strong> FY24: 1.91, FY23: 2.97. A decrease, reflecting the rise in debt from acquisitions, but still indicates the company has a strong ability to cover interest obligations.</li>
</ul>
<h3 class="heading" id="working-capital-ratios">
  Working Capital Ratios
  <a class="anchor" href="#working-capital-ratios">#</a>
</h3>
<ul>
<li><strong>Days of Inventory:</strong> FY24: 150.6 Days, FY23: 136.79 Days</li>
<li><strong>Days of Sales:</strong> FY24: 69.8 days, FY23: 67 days</li>
<li><strong>Days of Payables:</strong> FY24: 106.7 days, FY23: 75 days</li>
<li><strong>Net Working Capital Turnover Ratio:</strong> 3.69 in 2024, and 3.24 in 2023. The net working capital is increasing because of a significant increase in payables.</li>
</ul>
<h3 class="heading" id="comparison-with-industry-averages-and-significant-deviations">
  Comparison with Industry Averages and Significant Deviations
  <a class="anchor" href="#comparison-with-industry-averages-and-significant-deviations">#</a>
</h3>
<ul>
<li><strong>Profitability:</strong> The increase in profitability metrics are positive indicators of good company performance.</li>
<li><strong>Liquidity:</strong> The current ratio above 2 is generally considered healthy.</li>
<li><strong>Leverage:</strong> A decreasing debt-to-equity ratio and a solid interest coverage ratio demonstrate financial stability.</li>
<li><strong>Efficiency:</strong> The ratios are within the acceptable range.</li>
</ul>
<p>The material impact of the Company&rsquo;s acquisitions, expansions and other projects has clearly affected the current year ratios.</p>
<h2 class="heading" id="business-segments-performance-analysis">
  Business Segments Performance Analysis
  <a class="anchor" href="#business-segments-performance-analysis">#</a>
</h2>
<h3 class="heading" id="revenue-and-profitability-metrics-with-growth-rates">
  Revenue and Profitability Metrics with Growth Rates
  <a class="anchor" href="#revenue-and-profitability-metrics-with-growth-rates">#</a>
</h3>
<ul>
<li><strong>Domestic Formulations:</strong> FY24 revenue was ₹189,791 lakhs, a 16% growth year-on-year.</li>
<li><strong>International Business:</strong> FY24 revenue was ₹158,627 lakhs, a 5% growth year-on-year. Excluding South Africa business, revenue registered YoY growth of 12%.</li>
<li><strong>International Formulations:</strong> FY24 revenue was ₹106,854 lakhs representing a 6% increase.</li>
<li><strong>CDMO Business:</strong> FY24 revenue was ₹43,185 lakhs, demonstrating a 6% growth.</li>
<li><strong>API Business:</strong> FY24 sales were ₹8,588 lakhs, decreased from ₹9,359 lakhs in FY23.</li>
<li><strong>Consolidated Revenue:</strong> FY24 revenue reached ₹348,418 lakhs, an 11% growth year-on-year.</li>
<li><strong>Consolidated Operating EBITDA (excl. ESOP cost):</strong> Increased by 23%, from ₹76,513 lakhs to ₹93,886 lakhs.</li>
<li><strong>Consolidated profit before tax:</strong> Grew by 35%, from ₹55,523 lakhs to ₹75,151 lakhs.</li>
<li><strong>Consolidated Profit after tax:</strong> Increased by 35% to ₹55,263 lakhs from ₹41,001 lakhs in FY23.</li>
</ul>
<h3 class="heading" id="market-share-and-competitive-position">
  Market Share and Competitive Position
  <a class="anchor" href="#market-share-and-competitive-position">#</a>
</h3>
<ul>
<li><strong>Indian Pharmaceutical Market (IPM):</strong> Ranked #22 (IQVIA MAT Mar'24), up two positions, with a 10% year-on-year growth rate versus the industry growth of 8%.</li>
<li><strong>Chronic Therapies:</strong> Outperformed the IPM, growing at 14% versus the segment growth of 10%, holding a position among the top 20.</li>
<li><strong>Cardiology:</strong> Ranked #8 in the cardiology market and among top 10.</li>
<li><strong>Prescription Ranking:</strong> Ranked #16 in terms of prescriptions in the IPM.</li>
<li><strong>Ophthalmology:</strong> Ranks amongst the top 4 in covered market.</li>
</ul>
<h3 class="heading" id="key-productsservices-performance">
  Key Products/Services Performance
  <a class="anchor" href="#key-productsservices-performance">#</a>
</h3>
<ul>
<li><strong>Top Brands:</strong> Five brands (Cilacar, Rantac, Metrogyl, Cilacar-T, and Nicardia) are among the top 150 brands in the IPM.</li>
<li><strong>Cilacar Franchise:</strong> Registered 22% growth, and volume growth 11%</li>
<li><strong>Metrogyl Franchise:</strong> Crossed the ₹30,000 lakh mark.</li>
<li><strong>Razel Franchise:</strong> Registered a 24% of growth.</li>
<li><strong>Sporlac Franchise:</strong> Grew by 21% to ₹12,237 lakhs.</li>
<li><strong>Rantac and Metrogyl:</strong> Among the top 10 most prescribed brands in the IPM.</li>
</ul>
<h3 class="heading" id="geographic-distribution-and-market-penetration">
  Geographic Distribution and Market Penetration
  <a class="anchor" href="#geographic-distribution-and-market-penetration">#</a>
</h3>
<ul>
<li><strong>Direct Presence:</strong> Russia and South Africa.</li>
<li><strong>Distributor Relationships:</strong> U.S. and markets in Asia, Africa, and Latin America.</li>
<li><strong>Exports:</strong> To over 40 regulated and semi-regulated markets.</li>
<li><strong>International subsidiaries:</strong> Russia, South Africa and UAE.</li>
<li><strong>CDMO Business:</strong> Targets $100 million in revenue within the next three to five years</li>
</ul>
<h3 class="heading" id="segment-wise-capex-and-roic">
  Segment-wise CAPEX and ROIC
  <a class="anchor" href="#segment-wise-capex-and-roic">#</a>
</h3>
<ul>
<li>
<p><strong>Capital investment on energy conservation:</strong></p>
<ul>
<li><em>Panoli Unit:</em> ₹50 lakhs</li>
<li><em>Daman Unit:</em> ₹140 lakhs</li>
</ul>
</li>
<li>
<p><strong>Return on equity:</strong></p>
<ul>
<li>FY24: 18.92%</li>
<li>FY23: 16.53%</li>
</ul>
</li>
</ul>
<h3 class="heading" id="operational-efficiency-metrics">
  Operational Efficiency Metrics
  <a class="anchor" href="#operational-efficiency-metrics">#</a>
</h3>
<ul>
<li><strong>Field Force Productivity (excluding ophthalmology):</strong> Improved to ₹7 lakhs per person per month from ₹6.20 lakhs in FY23.</li>
<li><strong>Field Force productivity (including ophthalmology):</strong> Improved to ₹6.80 lakhs per person per month.</li>
<li><strong>Gross Margins:</strong> Increased from 62.9% to 66.1%.</li>
<li><strong>Operating EBITDA Margin (excl. ESOPs):</strong> Improved by 270 basis points to 27.0%.</li>
<li><strong>Net Working Capital:</strong> Improved to 87 days in FY24 from 98 days in FY21.</li>
<li><strong>Operating Cash Flows:</strong> Improved to 85% of operating EBITDA in FY24 from 56% in FY21.</li>
</ul>
<h3 class="heading" id="growth-initiatives-and-challenges">
  Growth Initiatives and Challenges
  <a class="anchor" href="#growth-initiatives-and-challenges">#</a>
</h3>
<ul>
<li>
<p><strong>Growth Initiatives:</strong></p>
<ul>
<li>Realigned Go-To-Market (GTM) model.</li>
<li>Increased focus on chronic therapies.</li>
<li>Strengthening of major brands.</li>
<li>Strategic acquisition of ophthalmology brands from Novartis.</li>
<li>Expansion of CDMO by addition of new concepts in logenzes.</li>
<li>New product launches in branded generics markets.</li>
</ul>
</li>
<li>
<p><strong>Challenges:</strong></p>
<ul>
<li>Muted acute season in India.</li>
<li>Lower South Africa revenue due to strategic decisions.</li>
<li>Elevated freight costs.</li>
<li>Geopolitical uncertainties impacting the international business environment.</li>
<li>Emission (Scope1 &amp; Scope2) intensity per rupee of turnover reduced by 25%</li>
<li>16.67% reduction in Scope 1 and Scope 2 emissions.</li>
<li>Energy intensity per rupee of turnover reduced by 18%</li>
<li>Water consumption intensity per rupee of turnover reduced by 9.4%.</li>
</ul>
</li>
</ul>
<h2 class="heading" id="forward-outlook-jb-chemicals--pharmaceuticals-limited-analysis">
  Forward Outlook: J.B. Chemicals &amp; Pharmaceuticals Limited Analysis
  <a class="anchor" href="#forward-outlook-jb-chemicals--pharmaceuticals-limited-analysis">#</a>
</h2>
<h3 class="heading" id="management-guidance-and-assumptions">
  Management Guidance and Assumptions
  <a class="anchor" href="#management-guidance-and-assumptions">#</a>
</h3>
<ul>
<li>Management anticipates sustained revenue growth, driven by domestic and CDMO businesses.</li>
<li>Management expects the IPM to experience improved growth, led by the chronic segment.</li>
<li>Strategic focus on diluting the low-margin South Africa business to improve overall margin profile.</li>
<li>Assumptions used to arrive at the valuation of acquired ophthalmology brands from Novartis.</li>
</ul>
<h3 class="heading" id="market-growth-forecasts">
  Market Growth Forecasts
  <a class="anchor" href="#market-growth-forecasts">#</a>
</h3>
<ul>
<li>The IPM grew at 8% in FY24.</li>
<li>The chronic segment within the IPM is forecasted to outperform the acute segment (14% vs. 10%).</li>
<li>The ophthalmology market is expected to grow at a 3-year CAGR of 15%.</li>
</ul>
<h3 class="heading" id="planned-strategic-initiatives">
  Planned Strategic Initiatives
  <a class="anchor" href="#planned-strategic-initiatives">#</a>
</h3>
<ul>
<li>Continued focus on the four-pillar strategy:
<ul>
<li>Realigned GTM model to drive productivity.</li>
<li>Increasing contribution from Chronic Therapies.</li>
<li>Making big brands bigger and building a strong franchise.</li>
<li>Acquisition-led growth via a strong brand franchise.</li>
</ul>
</li>
<li>Strategic focus on expanding the chronic portfolio.</li>
<li>Emphasis on heart failure, hypertension, and lipid management therapies within the cardiology segment.</li>
<li>Focus on new product introductions in the home and branded generics markets.</li>
<li>Expansion into newer areas within the CDMO business.</li>
<li>Planned diversification of the lozenge portfolio, entering into new categories like sleep disorder, pain management, immunity boosters, and anti-inflammatory products.</li>
<li>Introducing newer technologies to sustain technological lead in herbal and medicated lozenges manufacturing.</li>
<li>Target to achieve $100 million in revenue from the CDMO business within the next three to five years.</li>
</ul>
<h3 class="heading" id="capital-expenditure-plans">
  Capital Expenditure Plans
  <a class="anchor" href="#capital-expenditure-plans">#</a>
</h3>
<ul>
<li>Capital investment in energy conservation equipment of approximately ₹50 lakhs at the Panoli unit and ₹140 lakhs at the Daman unit.</li>
<li>Plans to expand manufacturing capacity annually, specifically for lozenges, anticipating rising demand.</li>
</ul>
<h3 class="heading" id="efficiency-improvement-targets">
  Efficiency Improvement Targets
  <a class="anchor" href="#efficiency-improvement-targets">#</a>
</h3>
<ul>
<li>Improvement in field force productivity, targeting ₹7 lakhs per person per month (excluding the ophthalmology portfolio).</li>
<li>Drive operational and cost efficiencies.</li>
<li>Improve EBITDA, profitability, net working capital, and operating cash flows.</li>
<li>Targeted improvement in gross margins and operating EBITDA (adjusted for non-cash ESOP costs).</li>
</ul>
<h3 class="heading" id="potential-challenges-and-opportunities">
  Potential Challenges and Opportunities
  <a class="anchor" href="#potential-challenges-and-opportunities">#</a>
</h3>
<h4 class="heading" id="challenges">
  Challenges
  <a class="anchor" href="#challenges">#</a>
</h4>
<ul>
<li>Geopolitical uncertainties impacting the cost environment and logistics, particularly in international operations.</li>
<li>Pricing pressure, particularly in international markets.</li>
</ul>
<h4 class="heading" id="opportunities">
  Opportunities
  <a class="anchor" href="#opportunities">#</a>
</h4>
<ul>
<li>Growth in the chronic segment of the IPM.</li>
<li>Opportunity in the CDMO business, especially in medicated and herbal lozenges.</li>
<li>Expansion in the rapidly expanding Ophthalmology market.</li>
<li>New launches in the branded generics markets.</li>
<li>Increase in demand in covered International markets.</li>
</ul>
<h3 class="heading" id="scenario-analysis-and-sensitivity-to-key-assumptions">
  Scenario Analysis and Sensitivity to Key Assumptions
  <a class="anchor" href="#scenario-analysis-and-sensitivity-to-key-assumptions">#</a>
</h3>
<ul>
<li><strong>Geopolitical Instability:</strong> A worsening of geopolitical issues presents a risk. Sensitivity analysis is not explicitly quantified, but the impact on freight costs and overall international business is acknowledged.</li>
<li><strong>IPM Growth:</strong> The company&rsquo;s domestic business performance is sensitive to the overall growth rate of the IPM and the specific growth rates of the chronic vs. acute segments.</li>
<li><strong>Exchange Rate Sensitivity:</strong> The provided data only provides a generic +/- 1% sensitivity to changes in major currencies (USD, EURO, RUB, AED, AUD, GBP, CAD, UAH) without details on the net effect on the Company&rsquo;s financial performance, only reporting the impact on the profit and other equity, with positive indicating an increase and negative indicating a decrease.</li>
</ul>
<h2 class="heading" id="audit-and-compliance-analysis">
  Audit and Compliance Analysis
  <a class="anchor" href="#audit-and-compliance-analysis">#</a>
</h2>
<h3 class="heading" id="auditors-opinion-and-qualifications">
  Auditor&rsquo;s Opinion and Qualifications
  <a class="anchor" href="#auditors-opinion-and-qualifications">#</a>
</h3>
<ul>
<li><strong>Auditor&rsquo;s Opinion:</strong> Unmodified opinion on the standalone and consolidated financial statements, indicating a true and fair view in conformity with Ind AS and other generally accepted accounting principles in India.</li>
<li><strong>Qualifications:</strong> A qualification is present regarding the maintenance of accounts, specfically: &ldquo;except for not complying with the requirement of audit trail as stated in (i)(vi) below&rdquo;. Audit trail was not enabled at the database level for direct data changes. In all other respect, proper books have been maintained.</li>
</ul>
<h3 class="heading" id="key-accounting-policies-and-changes">
  Key Accounting Policies and Changes
  <a class="anchor" href="#key-accounting-policies-and-changes">#</a>
</h3>
<ul>
<li><strong>Consistency:</strong> Accounting policies are applied consistently across all periods presented, except where new standards or revisions necessitate changes.</li>
<li><strong>Revenue Recognition:</strong> Revenue is recognized upon transfer of control of goods to the customer, net of estimated incentives, discounts, and returns.</li>
<li><strong>Foreign Currency Translation:</strong> Transactions are translated at the exchange rate prevailing on the transaction date. Monetary assets and liabilities are translated at the balance sheet date rate.</li>
<li><strong>Employee Benefits:</strong> Defined contribution plan expenses are recognized when the related service is rendered. Defined benefit plan costs are determined using the Projected Unit Credit method.</li>
<li><strong>Property, Plant and Equipment:</strong> Depreciation is provided on the straight-line method, with useful lives as prescribed in Schedule II of the Companies Act, 2013, with some exceptions based on technical evaluation.</li>
<li><strong>Intangible Assets:</strong> Amortization is provided over estimated useful lives, ranging from 2 to 25 years.</li>
<li><strong>Impairment of Non-Financial Assets:</strong> Annual assessment for impairment indicators is conducted.</li>
<li><strong>Inventories:</strong> Stated at the lower of cost or net realizable value. The cost is determined on the Moving Average Method.</li>
<li><strong>Leases:</strong> The Group has elected not to recognise right-of-use assets and liabilities for leases that, at the commencement date, have a term of 12 months or less or for low-value assets.</li>
</ul>
<h3 class="heading" id="internal-control-effectiveness">
  Internal Control Effectiveness
  <a class="anchor" href="#internal-control-effectiveness">#</a>
</h3>
<ul>
<li><strong>Auditor&rsquo;s Opinion:</strong> The Company has adequate internal financial controls over financial reporting, and these controls were operating effectively as of March 31, 2024.</li>
<li><strong>Risk Management:</strong> A Risk Management Committee is in place, delegated with monitoring and review of the risk management plan.</li>
</ul>
<h3 class="heading" id="regulatory-compliance-status">
  Regulatory Compliance Status
  <a class="anchor" href="#regulatory-compliance-status">#</a>
</h3>
<ul>
<li><strong>General Compliance:</strong> The Company has complied with applicable Secretarial Standards. Declarations of independence have been received from Independent Directors.</li>
<li><strong>Specific Compliance:</strong> The Company is compliant with provisions relating to the constitution of the Internal Complaints Committee under the Sexual Harassment of Women at Workplace Act, 2013.</li>
<li><strong>Cost Records:</strong> Cost records as specified by the Central Government are duly made and maintained.</li>
<li><strong>Audit Trail:</strong> The company used accounting software, but no audit trail enabled at the database level.</li>
</ul>
<h3 class="heading" id="legal-proceedings-and-their-potential-impact">
  Legal Proceedings and Their Potential Impact
  <a class="anchor" href="#legal-proceedings-and-their-potential-impact">#</a>
</h3>
<ul>
<li><strong>Pending Litigations:</strong> The Company has disclosed the impact of pending litigations on its financial position. Provisions have been made where required.</li>
<li><strong>Specific Cases:</strong> Demand notices from the Department of Chemicals &amp; Fertilizers for ₹461.47 lakhs (Metronidazole) and ₹591.05 lakhs (Oxyphenbutazone) are under dispute, with Writ Petitions filed. The Company has furnished a Bank Guarantee of ₹402.35 lakhs. Based on legal advice, the Company believes it has a strong case.</li>
<li>Contingent liabilities disclosed are central excise, service tax, customs, income tax and sales tax.</li>
</ul>
<h3 class="heading" id="related-party-transactions">
  Related Party Transactions
  <a class="anchor" href="#related-party-transactions">#</a>
</h3>
<ul>
<li><strong>Disclosure:</strong> Related party transactions were in the ordinary course of business and on an arm&rsquo;s length basis, with disclosures made as per Ind AS-24.</li>
<li><strong>Materiality:</strong> None of the related party transactions were deemed material under Regulation 23 of the Listing Regulations. No material conflict of interest.</li>
<li><strong>Transactions included:</strong> Remuneration to key management personnel and non-executive directors, transactions with holding and subsidiary companies (sales, purchases, ESOP receivables, etc.).</li>
</ul>
<h3 class="heading" id="subsequent-events">
  Subsequent Events
  <a class="anchor" href="#subsequent-events">#</a>
</h3>
<ul>
<li><strong>Proposed Dividend:</strong> The Board of Directors has recommended a final dividend of ₹6.75 per share, subject to shareholder approval.</li>
<li><strong>New Subsidiary:</strong> A new step-down subsidiary was incorporated in Philippines on April 2, 2024. Share capital in UPL FZE was augmented.</li>
</ul>
<h3 class="heading" id="accounting-quality-analysis">
  Accounting Quality Analysis
  <a class="anchor" href="#accounting-quality-analysis">#</a>
</h3>
<ul>
<li><strong>Conservative Approach:</strong> The Company appears to follow conservative accounting practices, as evidenced by the provisioning for expected credit losses, inventory obsolescence, and contingent liabilities.</li>
<li><strong>Detailed Disclosures:</strong> Comprehensive disclosures are made in accordance with Ind AS, providing transparency regarding financial instruments, related party transactions, and employee stock option schemes.</li>
</ul>
<h3 class="heading" id="regulatory-risk-assessment">
  Regulatory Risk Assessment
  <a class="anchor" href="#regulatory-risk-assessment">#</a>
</h3>
<ul>
<li><strong>General Compliance:</strong> High level of general compliance with the Companies Act, 2013, Listing Regulations, and other relevant laws.</li>
<li><strong>Audit trail:</strong> No trail for database-level entries.</li>
<li><strong>Litigation Risk:</strong> Some pending litigations, particularly with tax authorities, are present. However, the Company believes it has strong cases and has made necessary provisions.</li>
</ul>



<div class="button-container">    
    <a href="https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=28df5106-d74e-44a2-9fde-139e6b3c370d.pdf" target="_blank" class="report-button">
      <i class="fas fa-file-pdf"></i> Download Annual Report
    </a>
</div>
    



    
  </div>

  


  

  
  

<div class="single-pagination">
    <hr />

    <div class="flex">

        <div class="single-pagination-prev">
            
            <div class="single-pagination-container-prev">
                <div class="single-pagination-text">←</div>
                <div class="single-pagination-text">
                    <a href="/posts/avenue-supermarts-ltdannual-report-2023-24-analysis/">
                        Avenue Supermarts Ltd:Annual Report 2023-24 Analysis
                    </a>
                </div>
            </div>
            
        </div>

        <div class="single-pagination-next">
            
            <div class="single-pagination-container-next">
                <div class="single-pagination-text">
                    <a href="/posts/lloyds-metals--energy-ltdannual-report-2023-24-analysis/">
                        Lloyds Metals &amp; Energy Ltd:Annual Report 2023-24 Analysis
                    </a>
                </div>
                <div class="single-pagination-text">→</div>
            </div>
            
        </div>

    </div>

    <hr />
</div>



  <div id="disqus_thread"></div>
<script>
    

    

    (function() { 
    var d = document, s = d.createElement('script');
    s.src = 'https://muthuai.disqus.com/embed.js';
    s.setAttribute('data-timestamp', +new Date());
    (d.head || d.body).appendChild(s);
    })();
</script>
<noscript>Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript">comments powered by Disqus.</a></noscript>
  

  

  
  <div class="back-to-top">
    <a href="#top">
      back to top
    </a>
  </div>
  

</div>


    </main>
  </div>

  <footer>
    

    
    
    
    <p>Made with ♥ in India</p>
    


  </footer>

  

</body>

<script>

  function isAuto() {
    return document.body.classList.contains("auto");
  }

  function setTheme() {
    if (!isAuto()) {
      return
    }

    document.body.classList.remove("auto");
    let cls = "light";
    if (window.matchMedia && window.matchMedia('(prefers-color-scheme: dark)').matches) {
      cls = "dark";
    }

    document.body.classList.add(cls);
  }

  function invertBody() {
    document.body.classList.toggle("dark");
    document.body.classList.toggle("light");
  }

  if (isAuto()) {
    window.matchMedia('(prefers-color-scheme: dark)').addListener(invertBody);
  }

  setTheme();

</script>
<script>
    window.addEventListener('DOMContentLoaded', (event) => {
        new PagefindUI({ element: "#search", showSubResults: false, showImages: false });
    });
</script>
<script defer src="/js/copy-code.js"></script>
</html>